Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.64 |
| ▸ | FAP | Q12884 | 2/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.64 |
| ▸ | ACE | P12821 | 6/20 | 0.58 |
| ▸ | REN | P00797 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PEPD | P12955 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729262 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30729240 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL22498704 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL231856 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30179346 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL7405423 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5278976 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL25276458 | 0.95 | DPP4 (0.59) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1646849 | 0.95 | DPP4 (0.59) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1646847 | 0.95 | DPP4 (0.59) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118984702-A | Topical preparation for treating or preventing dry skin itch | MC2疗法有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118843470-A | Composition for metabolic health | 国际营养与健康丹麦有限公司 | 2024-10-25 | — | — | CN | claimed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| CN-118496322-A | Polypeptide inhibitor for targeted degradation of beta-catenin and application thereof | 昆明医科大学 | 2024-08-16 | — | — | CN | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| CN-117838878-A | Antibody-STING agonist conjugates and their use in immunotherapy | 免疫传感器治疗股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117677302-A | Peptide compounds for flavor modulation | CJ第一制糖株式会社 | 2024-03-08 | — | — | CN | claimed |
| US-20240059740-A1 | CYCLIC PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-02-22 | — | — | US | claimed |
| CN-117106028-B | Protease activated peptide and application thereof in preparation of medicines for preventing and/or treating myocardial ischemia/reperfusion injury | 首都医科大学附属北京朝阳医院 | 2024-02-13 | — | — | CN | claimed |
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2023-12-28 | — | — | US | claimed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | claimed |
| WO-2022133540-A1 | CYCLIC PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2022-06-30 | — | — | WO | claimed |
| EP-3999118-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | Immunesensor Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| WO-2022074228-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2022-04-14 | — | — | WO | claimed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | claimed |
| US-20150065366-A1 | Biomarkers for Bladder Cancer and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | claimed |
| CN-104204798-A | Biomarkers for bladder cancer and methods using the same | METABOLON INC | 2014-12-10 | — | — | CN | claimed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059740-A1 | CYCLIC PEPTIDES AND USES THEREOF | VIP, NGLY1, LNPEP | DPP4 1370/4885FAP 369/4885DPP8 1017/4885 |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | F3, F13B, TFPI | DPP4 982/4885FAP 598/4885DPP8 841/4885 |
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | PRKDC, DPM1, MMP8 | DPP4 487/4885FAP 291/4885DPP8 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.